Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Jury reaches partial verdict in Sean Combs trial, unable to reach verdict on Count One Republican Senator tells House not to ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...